Keywords: Phytopharm, Cogane, Parkinson's, Research
Phytopharm shares leap 350% on new Cogane data
Article | 15 October 2009
UK-based Phytopharm saw its share price rocket almost 350% to 26.75 pence, after the company announced encouraging results from two studies of its Cogane (PYM50028), a novel non-peptide, orally bioavailable neurotrophic factor inducer treatment for Parkinson's disease.
A non-clinical efficacy study showed oral administration of Cogane over 18 weeks significantly reduced parkinsonian disability by 43% in non-human primates. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
